Literature DB >> 20348222

Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload.

Karen M O'Shea1, David J Chess, Ramzi J Khairallah, Sharad Rastogi, Peter A Hecker, Hani N Sabbah, Kenneth Walsh, William C Stanley.   

Abstract

Recent data suggest adiponectin, an adipocyte-derived hormone, affects development of heart failure in response to hypertension. Severe short-term pressure overload [1-3 wk of transverse aortic constriction (TAC)] in adiponectin(-/-) mice causes greater left ventricle (LV) hypertrophy than in wild-type (WT) mice, but conflicting results are reported regarding LV remodeling, with either increased or decreased LV end diastolic volume compared with WT mice. Here we assessed the effects of prolonged TAC on LV hypertrophy and remodeling. WT and adiponectin(-/-) mice were subjected to TAC and maintained for 6 wk. Regardless of strain, TAC induced similar LV hypertrophy ( approximately 70%) and upregulation of mRNA for heart failure marker genes. However, LV chamber size was dramatically different, with classic LV dilation in WT TAC mice but concentric LV hypertrophy in adiponectin(-/-) mice. LV end diastolic and systolic volumes were lower and ejection fraction higher in adiponectin(-/-) TAC mice compared with WT, indicating that adiponectin deletion prevented LV remodeling and deterioration in systolic function. The activities of marker enzymes of mitochondrial oxidative capacity were reduced in WT TAC mice by approximately 35%, whereas enzyme activities were maintained at sham levels in adiponectin(-/-) TAC mice. In conclusion, in WT mice, long-term pressure overload caused dilated LV hypertrophy accompanied by decreased activity of mitochondrial oxidative enzymes. Although adiponectin deletion did not affect LV hypertrophy, it prevented LV chamber remodeling and preserved mitochondrial oxidative capacity, suggesting that adiponectin plays a permissive role in mediating changes in cardiac structure and metabolism in response to pressure overload.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348222      PMCID: PMC2886648          DOI: 10.1152/ajpheart.00957.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

Review 1.  Myocardial substrate metabolism in the normal and failing heart.

Authors:  William C Stanley; Fabio A Recchia; Gary D Lopaschuk
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

Review 2.  The role of the adipocyte hormone adiponectin in cardiovascular disease.

Authors:  Christopher Hug; Harvey F Lodish
Journal:  Curr Opin Pharmacol       Date:  2005-04       Impact factor: 5.547

3.  Adiponectin-mediated modulation of hypertrophic signals in the heart.

Authors:  Rei Shibata; Noriyuki Ouchi; Masahiro Ito; Shinji Kihara; Ichiro Shiojima; David R Pimentel; Masahiro Kumada; Kaori Sato; Stephan Schiekofer; Koji Ohashi; Tohru Funahashi; Wilson S Colucci; Kenneth Walsh
Journal:  Nat Med       Date:  2004-11-21       Impact factor: 53.440

4.  Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.

Authors:  H N Sabbah; W C Stanley; V G Sharov; T Mishima; M Tanimura; C R Benedict; S Hegde; S Goldstein
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

5.  Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload.

Authors:  Ping Hu; Dongfang Zhang; LeAnne Swenson; Gopa Chakrabarti; E Dale Abel; Sheldon E Litwin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

6.  Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells.

Authors:  Noriyuki Ouchi; Hideki Kobayashi; Shinji Kihara; Masahiro Kumada; Kaori Sato; Tatsuya Inoue; Tohru Funahashi; Kenneth Walsh
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

7.  Hypoadiponectinemia is an independent risk factor for hypertension.

Authors:  Yoshio Iwashima; Tomohiro Katsuya; Kazuhiko Ishikawa; Noriyuki Ouchi; Mitsuru Ohishi; Ken Sugimoto; Yuxiao Fu; Masaharu Motone; Kouichi Yamamoto; Akiko Matsuo; Koji Ohashi; Shinji Kihara; Tohru Funahashi; Hiromi Rakugi; Yuji Matsuzawa; Toshio Ogihara
Journal:  Hypertension       Date:  2004-05-03       Impact factor: 10.190

8.  Association of hypoadiponectinemia with coronary artery disease in men.

Authors:  Masahiro Kumada; Shinji Kihara; Satoru Sumitsuji; Toshiharu Kawamoto; Satoru Matsumoto; Noriyuki Ouchi; Yukio Arita; Yoshihisa Okamoto; Iichiro Shimomura; Hisatoyo Hiraoka; Tadashi Nakamura; Tohru Funahashi; Yuji Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

9.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.

Authors:  Norikazu Maeda; Iichiro Shimomura; Ken Kishida; Hitoshi Nishizawa; Morihiro Matsuda; Hiroyuki Nagaretani; Naoki Furuyama; Hidehiko Kondo; Masahiko Takahashi; Yukio Arita; Ryutaro Komuro; Noriyuki Ouchi; Shinji Kihara; Yoshihiro Tochino; Keiichi Okutomi; Masato Horie; Satoshi Takeda; Toshifumi Aoyama; Tohru Funahashi; Yuji Matsuzawa
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  15 in total

Review 1.  The evolving role of adiponectin as an additive biomarker in HFrEF.

Authors:  Tahnee Sente; Andreas Gevaert; An Van Berendoncks; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 2.  Cardiometabolic effects of adiponectin.

Authors:  Jennifer L Parker-Duffen; Kenneth Walsh
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 4.690

3.  Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling.

Authors:  Eric E Essick; Noriyuki Ouchi; Richard M Wilson; Koji Ohashi; Joanna Ghobrial; Rei Shibata; David R Pimentel; Flora Sam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-10       Impact factor: 4.733

Review 4.  Direct effects of adipokines on the heart: focus on adiponectin.

Authors:  Min Park; Gary Sweeney
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

5.  C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart.

Authors:  Wei Yi; Yang Sun; Yuexing Yuan; Wayne Bond Lau; Qijun Zheng; Xiaoliang Wang; Yajing Wang; Xiying Shang; Erhe Gao; Walter J Koch; Xin-Liang Ma
Journal:  Circulation       Date:  2012-05-31       Impact factor: 29.690

6.  Adiponectin downregulation is associated with volume overload-induced myocyte dysfunction in rats.

Authors:  Li-li Wang; Dori Miller; Desiree Wanders; Gayani Nanayakkara; Rajesh Amin; Robert Judd; Edward E Morrison; Ju-ming Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-30       Impact factor: 6.150

7.  Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.

Authors:  Joshua Abd Alla; Muriel Graemer; Xuebin Fu; Ursula Quitterer
Journal:  J Biol Chem       Date:  2015-12-15       Impact factor: 5.157

8.  ω-3 Polyunsaturated fatty acids prevent pressure overload-induced ventricular dilation and decrease in mitochondrial enzymes despite no change in adiponectin.

Authors:  Karen M O'Shea; David J Chess; Ramzi J Khairallah; Peter A Hecker; Biao Lei; Kenneth Walsh; Christine Des Rosiers; William C Stanley
Journal:  Lipids Health Dis       Date:  2010-09-06       Impact factor: 3.876

9.  Adiponectin in cardiovascular inflammation and obesity.

Authors:  Tamar R Aprahamian; Flora Sam
Journal:  Int J Inflam       Date:  2011-09-15

10.  Adiponectin action: a combination of endocrine and autocrine/paracrine effects.

Authors:  Keith Dadson; Ying Liu; Gary Sweeney
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-08       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.